Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-CABG: Autologous CD133+ Stem Cells in CABG
NCT01467232Phase 2Completed
- Sponsor
- University Health Network
- Start
- Sep 2011
- Primary completion
- Nov 2014
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous CD133+ cells in ischemic cardiomyopathy (ICM), heart failure (HF), sponsored by University Health Network. Started Sep 2011; status: completed.
02
Drugs
autologous CD133+ cells
03
Conditions
ischemic cardiomyopathy (ICM)heart failure (HF)
Beyond the preview
Go deeper on NCT01467232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01467232.